(NEW YORK) — A new study suggests that GLP-1 agonist medications like Ozempic, which are used for diabetes management and weight loss, may help reduce the risk of overdose and alcohol intoxication in people with substance use disorders.
“It helps to underline another significant benefit of this class of medication,” Dr. Angela Fitch, the co-founder, and chief medical officer of knownwell, a company that provides weight-inclusive health care, told ABC News.
The large study, published in the journal, Addiction, analyzed the health records of 1.3 million people from 136 U.S. hospitals for nearly nine years. That included the records of 500,000 people with opioid use and more than 800,000 with alcohol use disorder.
Those who took Ozempic or a similar drug had a 40% lower chance of overdosing on opioids and a 50% lower chance of getting drunk compared to those who didn’t take the medication, the study found.
“The existing medications for treating substance use disorder are underutilized and stigmatized,” said Fares Qeadan, associate professor of biostatistics at Loyola University in Chicago. “These medications intended for diabetes and weight loss can help addiction without the associated stigma, which will be a new window for how to deal with addiction.”
The protective effects were consistent and even applied to people with Type 2 diabetes, obesity, or both conditions.
Fitch expressed optimism about the study’s results.
“As clinicians, recognizing that people can get double benefits from something is always helpful and as more obesity medications enter the market, this can help personalize treatments,” she said.
GLP-1 drugs, such as Ozempic and the combination drug tirzepatide also included in the study, mimic a natural hormone known as glucagon-like peptide-1 to help regulate blood sugar and insulin levels. For managing obesity and diabetes, these medications work by slowing digestion, reducing appetite, and enhancing insulin release in response to meals.
Scientists don’t fully understand how these drugs work yet. Some studies indicate that they activate specific “reward” receptors in the brain that make high-calorie foods less gratifying, so users eat less.
This could also be the reason these drugs may reduce cravings for alcohol and opioids. For example, a previous study found that adding the GLP-1, exenatide, was effective at helping some people with obesity and alcohol use disorder drink less.
The Addiction study does not prove that GLP-1 medications directly lower the risks of opioid overdose and alcohol intoxication, only that people taking them seemed to be helped. And it only included hospitalizations so it’s not clear if they will work as well in less serious cases.
Prescribing the drugs to treat substance use, at least for now, isn’t possible because they aren’t approved by the U.S. Food and Drug Administration for that purpose, Fitch pointed out.
“One of the challenges that we have as clinicians is we know that some of these benefits help patients. And not being able to get them access is very challenging,” she said.
People with substance use disorder keep using drugs or alcohol even though it causes problems in their life. According to the CDC, there are 178,000 annual deaths linked to excessive drinking. Over 75% of drug overdose deaths in 2022 involved opioids.
If you or someone you know is living with substance use disorder, free, confidential help is available 24 hours a day, seven days a week, by calling or texting the national lifeline at 988.
Dr. Faizah Shareef is an Internal Medicine Resident Physician and a member of the ABC News Medical Unit.
Copyright © 2024, ABC Audio. All rights reserved.
